Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBRXNASDAQ:IMVTNASDAQ:PRVLNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$2.84+6.4%$2.64$1.83▼$8.07$2.51B0.335.48 million shs8.71 million shsIMVTImmunovant$14.46+3.9%$15.92$12.72▼$34.47$2.46B0.751.22 million shs1.09 million shsPRVLPrevail Therapeutics$23.00$23.01$9.02▼$23.35$787.66M1.59955,800 shsN/ASRRKScholar Rock$30.55-0.9%$31.19$6.76▼$46.98$2.90B0.371.27 million shs1.08 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio+7.23%+27.75%-3.96%-26.24%-67.04%IMVTImmunovant+1.02%-2.66%-10.02%-31.53%-55.00%PRVLPrevail Therapeutics0.00%0.00%0.00%0.00%0.00%SRRKScholar Rock+0.95%-0.75%+2.02%-16.83%+119.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBRXImmunityBio1.816 of 5 stars3.51.00.00.01.91.70.6IMVTImmunovant2.6361 of 5 stars4.51.00.00.03.11.70.0PRVLPrevail TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASRRKScholar Rock4.0943 of 5 stars3.50.00.04.43.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBRXImmunityBio 3.00Buy$12.19329.14% UpsideIMVTImmunovant 2.90Moderate Buy$38.33165.10% UpsidePRVLPrevail Therapeutics 0.00N/AN/AN/ASRRKScholar Rock 3.00Buy$42.6739.66% UpsideCurrent Analyst Ratings BreakdownLatest PRVL, SRRK, IMVT, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/12/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/12/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/5/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/28/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/23/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.004/16/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/15/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/9/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/31/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBRXImmunityBio$31.22M80.28N/AN/A($0.88) per share-3.23IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/APRVLPrevail TherapeuticsN/AN/AN/AN/A$4.85 per shareN/ASRRKScholar Rock$33.19M87.31N/AN/A$3.12 per share9.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBRXImmunityBio-$583.20M-$0.58N/AN/AN/A-8,016.83%N/A-110.02%N/AIMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)PRVLPrevail Therapeutics-$63.19M-$2.22N/AN/AN/AN/A-55.57%-48.14%N/ASRRKScholar Rock-$165.79M-$2.45N/AN/AN/AN/A-145.60%-91.83%N/ALatest PRVL, SRRK, IMVT, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q4 2025IMVTImmunovant-$0.72N/AN/AN/AN/AN/A5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million3/3/2025Q4 2024IBRXImmunityBio-$0.26-$0.15+$0.11-$0.09$8.74 million$7.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBRXImmunityBioN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/APRVLPrevail TherapeuticsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBRXImmunityBioN/A2.682.64IMVTImmunovantN/A6.046.04PRVLPrevail TherapeuticsN/A7.567.56SRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBRXImmunityBio8.58%IMVTImmunovant47.08%PRVLPrevail Therapeutics86.80%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipIBRXImmunityBio76.79%IMVTImmunovant5.90%PRVLPrevail Therapeutics57.20%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBRXImmunityBio590882.62 million115.67 millionOptionableIMVTImmunovant120169.86 million159.84 millionOptionablePRVLPrevail Therapeutics6634.25 millionN/ANot OptionableSRRKScholar Rock14094.86 million75.64 millionOptionablePRVL, SRRK, IMVT, and IBRX HeadlinesRecent News About These CompaniesScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16 at 4:15 PM | businesswire.comMPM Bioimpact LLC Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 16 at 8:38 AM | marketbeat.com400,000 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Acquired by Paradigm Biocapital Advisors LPMay 16 at 8:35 AM | marketbeat.comPatient Square Capital LP Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 16 at 8:10 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by Ensign Peak Advisors IncMay 16 at 4:44 AM | marketbeat.comBaird Financial Group Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 16 at 4:17 AM | marketbeat.comScholar Rock (NASDAQ:SRRK) Shares Gap Down Following Weak EarningsMay 16 at 1:37 AM | americanbankingnews.comEarnings call transcript: Scholar Rock’s Q1 2025 results show slight EPS miss, stock reacts positivelyMay 15 at 11:35 PM | investing.comEarnings call transcript: Scholar Rock’s Q1 2025 results show slight EPS miss, stock reacts positivelyMay 15 at 11:35 PM | investing.comScholar Rock Holding Corp (SRRK) Q1 2025 Earnings Call Highlights: Strong Progress and ...May 15 at 11:35 PM | finance.yahoo.comScholar Rock signals Q3 US launch for apitegromab with $364.4M in cash on hand while advancing global expansion plansMay 15 at 11:35 PM | msn.comScholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2025 Earnings Call TranscriptMay 15 at 11:35 PM | msn.comOrbimed Advisors LLC Sells 590,500 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 15 at 7:52 AM | marketbeat.comOctagon Capital Advisors LP Invests $21.09 Million in Scholar Rock Holding Co. (NASDAQ:SRRK)May 15 at 7:39 AM | marketbeat.comScholar Rock reports Q1 loss, shares edge higherMay 14 at 10:50 AM | investing.comScholar Rock Reports First Quarter 2025 Financial Results and Highlights Business ProgressMay 14 at 10:50 AM | finance.yahoo.comIntegral Health Asset Management LLC Boosts Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)May 14 at 6:17 AM | marketbeat.comA Look Ahead: Scholar Rock Holding's Earnings ForecastMay 13 at 7:47 PM | benzinga.comJasper Ridge Partners L.P. Raises Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 13 at 7:55 AM | marketbeat.comFred Alger Management LLC Purchases Shares of 38,172 Scholar Rock Holding Co. (NASDAQ:SRRK)May 13 at 6:03 AM | marketbeat.comD. E. Shaw & Co. Inc. Has $28.82 Million Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)May 13 at 6:02 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRVL, SRRK, IMVT, and IBRX Company DescriptionsImmunityBio NASDAQ:IBRX$2.84 +0.17 (+6.37%) Closing price 04:00 PM EasternExtended Trading$2.80 -0.03 (-1.23%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Immunovant NASDAQ:IMVT$14.46 +0.54 (+3.88%) Closing price 04:00 PM EasternExtended Trading$14.00 -0.46 (-3.18%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Prevail Therapeutics NASDAQ:PRVLPrevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.Scholar Rock NASDAQ:SRRK$30.55 -0.28 (-0.91%) Closing price 04:00 PM EasternExtended Trading$29.96 -0.59 (-1.93%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
